Drugs / Typhocon
Typhocon
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05475379 | Jul 2022 → Jun 2023 | typhoid fever | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Typhocon | “Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT). Trade name: Typhocon®, Incepta Vaccine Ltd.” NCT05475379 ↗ |
| Known as | Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT) | “Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT). Trade name: Typhocon®, Incepta Vaccine Ltd.” NCT05475379 ↗ |
| Known as | Vi-DT | “Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT). Trade name: Typhocon®, Incepta Vaccine Ltd.” NCT05475379 ↗ |